Related Experiment Video
Updated: Jul 24, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Possible neuroprotective therapy for Parkinson's disease
1Department of Neuroscience, Okayama University Medical School, Japan.
Acta Medica Okayama
|August 1, 1995
Summary
Neuroprotective therapies for Parkinson's disease (PD) aim to prevent neuronal loss. Research suggests free radicals are key in PD progression, leading to strategies like reducing levodopa dosage and using dopamine agonists.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- Parkinson's disease (PD) is characterized by progressive neurodegeneration.
- Free radicals are implicated as a primary factor in PD pathogenesis.
- Evaluating neuroprotective therapies requires lengthy clinical trials.
Purpose of the Study:
- To review current and potential neuroprotective strategies for Parkinson's disease.
- To highlight the role of free radicals in PD progression.
- To discuss the clinical applicability of experimental neuroprotective agents.
Main Methods:
- Review of in vitro and animal studies on neuroprotective agents.
- Analysis of levodopa's role in free radical formation.
- Evaluation of dopamine metabolism inhibition and dopamine agonists (e.g., bromocriptine) for neuroprotection.
Main Results:
- Levodopa dose reduction is a potential neuroprotective strategy due to its association with free radical formation.
- Dopamine metabolism inhibition and bromocriptine demonstrate experimental neuroprotective effects by reducing free radicals.
- Several candidate neuroprotective agents are under development.
Conclusions:
- Experimental evidence supports strategies targeting free radicals for PD neuroprotection.
- Clinical consideration of approved agents is warranted for patients with long-standing PD.
- Further research and clinical validation are needed for novel neuroprotective therapies in Parkinson's disease.
Related Concept Videos
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...